Hodgkin's Lymphoma Treatment Market Report 2026

Hodgkin's Lymphoma Treatment Market Overview

• Hodgkin's Lymphoma Treatment market size has reached to $3.56 billion in 2025 • Expected to grow to $5.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Increasing Global Incidence Of Hodgkin’s Lymphoma Fueling Market Growth Due To Rising Patient Population And Treatment Demand • Market Trend: Expanding Front?Line Targeted Combination Therapy To Improve Patient Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hodgkin's Lymphoma Treatment Market?

Hodgkin's lymphoma treatment refers to the medical approaches used to manage and cure Hodgkin's lymphoma, a type of cancer that affects the lymphatic system. It involves therapies such as chemotherapy, radiation therapy, and targeted immunotherapy to eliminate cancerous cells and prevent disease progression. The treatment aims to achieve remission, improve survival rates, and enhance the quality of life for patients. The main type of treatments Hodgkin's lymphoma treatment include chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Chemotherapy refers to a medical treatment that uses drugs to destroy or inhibit the growth of cancer cells in the body. The disease types covered are classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The treatment stages include early-stage, advanced-stage, and relapsed conditions. The stem cell transplantation options include autologous stem cell transplant and allogeneic stem cell transplant. The key end users include hospitals, specialty clinics, cancer centers, ambulatory care centers, and home healthcare services.

What Is The Hodgkin's Lymphoma Treatment Market Growth Forecast?

The hodgkin's lymphoma treatment market size is expected to see strong growth in the next few years. It will grow to $5.08 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to rising adoption of immunotherapy and targeted therapies, growing availability of stem cell transplantation, increasing patient preference for personalized treatments, expansion of cancer centers in emerging markets, rising insurance coverage and reimbursement support. Major trends in the forecast period include technology advancements in diagnostic imaging, innovations in immunotherapy and targeted therapies, developments in minimally invasive treatment options, research and developments in stem cell transplantation, integration of digital health and telemedicine in follow-up care.

Global Hodgkin's Lymphoma Treatment Market Segmentation

1) By Type of Treatment: Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy 2) By Disease Type: Classical Hodgkin Lymphoma (CHL), Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) 3) By Treatment Stage: Early-Stage, Advanced-Stage, Relapsed 4) By Stem Cell Transplantation: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant 5) By End-Use: Hospitals, Specialty Clinics, Cancer Centers, Ambulatory Care Centers, Home Healthcare Services Subsegments: 1) By Chemotherapy: Combination Chemotherapy, Single Agent Chemotherapy, High Dose Chemotherapy with Stem Cell Transplantation 2) By Radiation Therapy: External Beam Radiation Therapy, Proton Beam Radiation Therapy, Intensity Modulated Radiation Therapy 3) By Targeted Therapy: Monoclonal Antibody Therapy, Antibody Drug Conjugate Therapy, Small Molecule Inhibitor Therapy 4) By Immunotherapy: Immune Checkpoint Inhibitor Therapy, Chimeric Antigen Receptor T Cell Therapy, Cytokine Based Immunotherapy

What Is The Driver Of The Hodgkin's Lymphoma Treatment Market?

The increasing incidence of Hodgkin’s lymphoma is expected to propel the growth of the Hodgkin’s lymphoma treatment market going forward. Hodgkin’s lymphoma refers to a cancer of the lymphatic system characterized by abnormal Reed–Sternberg cells in lymph nodes, typically affecting B‑lymphocytes and often presenting with painless swollen glands, fever, night sweats, and weight loss. The incidence of Hodgkin’s lymphoma is rising due to growing exposure to risk factors such as smoking, obesity, hypertension and changing socioeconomic conditions in many regions contributes to higher disease occurrence over time. Hodgkin’s lymphoma treatment helps in managing Hodgkin’s lymphoma by targeting and eliminating cancerous lymphocytes through therapies such as chemotherapy, radiation, or immunotherapy. It improves patient outcomes by reducing disease progression, achieving remission, and enhancing overall survival rates. For instance, in October 2025, according to the American Cancer Society, a US-based nonprofit organization, Hodgkin lymphoma in the United States is estimated to account for about 8,720 new cases, including 4,840 in males and 3,880 in females and about 1,150 deaths, including 720 males and 430 females. Therefore, the increasing incidence of Hodgkin’s lymphoma is driving the growth of the Hodgkin’s lymphoma treatment market.

Key Players In The Global Hodgkin's Lymphoma Treatment Market

Major companies operating in the hodgkin's lymphoma treatment market are F. Hoffmann‑La Roche Ltd., Merck & Co. Inc., Pfizer Inc., Novartis AG, AstraZeneca plc, Bristol‑Myers Squibb Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Ono Pharmaceutical Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Seagen Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., BeiGene Ltd., Innovent Biologics Inc., HUTCHMED (China) Limited, Aurigene Discovery Technologies Limited, ADC Therapeutics SA, CStone Pharmaceuticals, Emcure Pharmaceuticals Ltd., Sorrento Therapeutics Inc.

Global Hodgkin's Lymphoma Treatment Market Trends and Insights

Major companies operating in the Hodgkin’s lymphoma treatment market are focusing on developing advanced treatments, such as front‑line targeted combination therapies, to improve treatment effectiveness, reduce treatment‑related morbidity, and broaden first‑line options for patients with advanced disease. Front‑line targeted combination therapies refer to using two or more precision medicines together as the initial treatment to simultaneously hit multiple disease-driving pathways improve response rates and delay resistance in newly diagnosed patients. For instance, in June 2025, Takeda, a Japan‑based pharmaceutical company, received European Commission approval for ADCETRIS in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) for adults with newly diagnosed Stage IIb with risk factors, Stage III, or Stage IV Hodgkin lymphoma, based on Phase 3 HD21 trial results showing superior safety and non‑inferior progression‑free survival versus standard eBEACOPP chemotherapy. This front‑line targeted combination therapy features a targeted ADC backbone, a chemotherapy‑optimized regimen designed to lower acute toxicity, and expanded indications into frontline treatment, representing a significant advance in Hodgkin’s lymphoma care.

What Are Latest Mergers And Acquisitions In The Hodgkin's Lymphoma Treatment Market?

In March 2023, Pfizer Inc., a US-based global biopharmaceutical company, acquired Seagen Inc. for approximately $43 billion. With this acquisition, Pfizer aims to strengthen its Hodgkin’s lymphoma treatment portfolio by integrating Seagen’s antibody-drug conjugate technology and marketed oncology medicines, including ADCETRIS brentuximab vedotin which is indicated for classical Hodgkin’s lymphoma, thereby enhancing its targeted oncology capabilities, and expanding treatment options for hematologic malignancies. Seagen Inc. is a US-based biotechnology company developing ADCETRIS (brentuximab vedotin) which is approved for the treatment of certain forms of Hodgkin lymphoma.

Regional Insights

North America was the largest region in the hodgkin's lymphoma treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hodgkin's lymphoma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hodgkin's lymphoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hodgkin's Lymphoma Treatment Market?

The Hodgkin's lymphoma treatment market consists of sales of products such as chemotherapy drugs (e.g., doxorubicin, bleomycin, vinblastine, dacarbazine), targeted therapies (e.g., brentuximab vedotin), immunotherapy agents (e.g., checkpoint inhibitors), radiopharmaceuticals, monoclonal antibodies, combination therapy regimens, supportive care medications, and stem cell transplantation products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hodgkin's Lymphoma Treatment Market Report 2026?

The hodgkin's lymphoma treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hodgkin's lymphoma treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.